
Trump Administration Executive Order (EO) Tracker
On January 31, 2023, Commissioner Califf announced a new vision for the U.S. Food and Drug Administration (FDA)’s Human Foods Program. The Proposal calls for unifying the work currently done by the Center for Food Safety and Applied Nutrition (CFSAN), the Office of Food Policy and Response (OFPR), as well as certain functions within the Office of Regulatory Affairs (ORA), into a single organization under the leadership of a Deputy Commissioner for Human Foods. Pending development of “a concrete organizational proposal,” CFSAN, OFPR and ORA will continue to operate under their current structures. FDA will provide a further public update on its progress by the end of February 2023.
Last year’s infant formula recall and subsequent supply shortage led to considerable external scrutiny and criticism of FDA’s Human Foods Program (the Program). That criticism intensified in the wake of news articles reporting agency infighting and severe resource shortfalls. In response, FDA Commissioner Robert Califf asked the Reagan-Udall Foundation for the FDA (RUF) to conduct an independent evaluation of the Program, culminating in a report released on December 6, 2022.1 The RUF’s report identified a number of opportunities to strengthen the Program, which the agency reviewed in connection with Commissioner Califf’s announcement of this “new, transformative vision” for the Program.”2 The elements of this proposed reorganization are summarized below.
The new vision for the Program calls for combining the functions of CFSAN, OFPR, and certain portions of ORA into a single organization with “clear priorities that are focused on protecting and promoting a safe, nutritious U.S. food supply that more quickly adapts to an ever-changing and evolving environment.” The Program will be overseen by a Deputy Commissioner for Human Foods who will have decision-making authority over policy, strategy, and regulatory program activities, as well as resource allocation and risk-prioritization. The Deputy Commissioner will report directly to the FDA Commissioner.
The vision also includes creation of the following new elements of the Human Foods Program:
The new vision also calls for changes to the Center of Veterinary Medicine (CVM) and ORA. Although CVM will continue to operate as a stand-alone center, FDA promises that “the relevant food safety activities will be closely coordinated” between the CVM Center Director and the Deputy Commissioner for Foods. In addition, the role of the CVM Director will expand to include the duties of Chief Veterinary Officer (in instances when this individual is a veterinarian) and an Office of Animal Biotechnology Innovation will be created. ORA will be “transformed into an enterprise-wide organization” that supports all regulatory programs, including foods, through a focus on core activities (e.g., inspections, investigations, laboratory analysis, and import operations). The agency plans to “better integrate” ORA with all FDA programs through 1) improving the risk prioritization and public health impact of FDA’s field activities, 2) modernizing those field activities, and 3) creating operational efficiencies.
FDA will conduct a nationwide search to identify the new Deputy Commissioner for Human Foods and provide another public update on its overall progress on the new vision by the end of February 2023. We will continue to monitor the agency’s reorganization plans. In the meantime, please contact us if you have any questions.
Authored by Maile Gradison, Andrea Bruce, and Molly Mulligan.
References